Hematologic Malignancies Disease Management Group Research
The Hematologic Malignancies Disease Management Group (DMG) at Perlmutter Cancer Center investigates the etiology and treatment of lymphoma, leukemia, multiple myeloma, and other malignancies of the blood and bone marrow.
We maintain a wide-ranging portfolio of clinical and laboratory research to evaluate emerging agents for hematologic cancers. Through our research, we seek an understanding of how abnormalities can be targeted to develop better therapies and improve outcomes for patients with hematologic malignancies. Our clinical trial protocols are available for nearly all stages and types of lymphoma, including both untreated and previously treated patients.
Our hematology oncologists, pediatric hematology oncologists, radiation oncologists, and pathologists meet weekly to discuss patient management, often consulting radiologists, hematopathologists, cytogeneticists, and molecular pathologists. The stem cell transplant team—including pharmacists, nutritionists, nurses, and administrators—meets biweekly to discuss candidates for transplant, patient management, and new research clinical protocols.
Hematologic Malignancies Research Leadership
Michael L. Grossbard, MD
Chief, Hematology and Medical Oncology Inpatient Service, Tisch Hospital
Section Chief, Hematology, Perlmutter Cancer Center
Professor, Department of Medicine
Naamit K. Gerber, MD
Assistant Professor, Department of Radiation Oncology
Hematologic Malignancies Research Areas of Focus
Our research scientists focus on molecular abnormalities found in acute lymphoblastic leukemia, myeloma, and myeloproliferative neoplasms.
Our basic and translational science investigators are studying recurrent mutations found in relapsed acute leukemia, the importance of adhesion molecules, and the bone marrow niche in acute leukemia. We are also studying mutations in the ubiquitin ligase system in myeloma and lymphoma and the role of the JAK/STAT pathway in stem cell biology, cutaneous cell lymphoma, and myeloproliferative disorders.
Current studies encompass epigenetic therapy in pediatric leukemia, immune therapy in Hodgkin lymphoma, and microbiome in non-Hodgkin lymphoma. We are studying STAT3 inhibition in cutaneous T-cell lymphoma, and the use of palbociclib, a selective inhibitor, in acute lymphocytic leukemia, myeloma, and mantle cell lymphoma. Additional studies focus on the role of vitamin C in myelodysplasia.
Our clinical research trials focus primarily on lymphoma and leukemia, seeking novel agents such as antibodies and immunotherapy. We developed a large national trial to study the combination of targeted therapies and immunotherapy for patients with relapsed Hodgkin lymphoma, and we study haploidentical allogeneic stem cell transplant in the treatment of hematologic malignancies.